66 Biggest Movers From Friday
Gainers
Bakkt Holdings, Inc. (NASDAQ: BKKT) shares surged 66.1% to close at $42.52 on Friday on continued volatility after the company recently announced partnerships with Mastercard and Fiserv.
There Are Now 50 Psychedelics Companies Listed In The U.S. – Here They Are
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors.
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Psilocybin Alpha.
In just a couple of years, psychedelics took the world of investing by storm.
Field Trip Health Heads To The Nasdaq As Wall Street Opens Up To “Psychedelics Renaissance”
Excitement around psychedelics grows as major U.S. exchanges make room for more companies in the sector.
Cowen & Co. Initiates Coverage On GH Research with Outperform Rating
Cowen & Co. analyst Ritu Baral initiates coverage on GH Research (NASDAQ:GHRS) with a Outperform rating.
JMP Securities Initiates Coverage On GH Research with Outperform Rating, Announces Price Target of $35
JMP Securities analyst Jason Butler initiates coverage on GH Research (NASDAQ:GHRS) with a Outperform rating and announces Price Target of $35.
Stifel Initiates Coverage On GH Research with Buy Rating, Announces Price Target of $26
Stifel analyst Paul Matteis initiates coverage on GH Research (NASDAQ:GHRS) with a Buy rating and announces Price Target of $26.
Canaccord Genuity Initiates Coverage On GH Research with Buy Rating, Announces Price Target of $35
Canaccord Genuity analyst Sumant Kulkarni initiates coverage on GH Research (NASDAQ:GHRS) with a Buy rating and announces Price Target of $35.